Cellular senescence mediates facioscapulohumeral muscular dystrophy
Journal of Clinical Investigation · 05.11.2026
DOI: 10.1172/jci207716 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Investigation, online erschienen am 05.11.2026. Verfasst von Usuk Jung und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics and Lillehei Heart Institute, University of Minnesota, Minneapolis, United States of America. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIH.
Abstract (Originalsprache)
Facioscapulohumeral muscular dystrophy (FSHD) is driven by aberrant expression of the early embryonic transcription factor Double Homeobox 4 (DUX4), yet the mechanisms linking low, sporadic DUX4 activity to progressive muscle degeneration remain unclear. Here, we identify cellular senescence as a central and early mechanism in FSHD pathogenesis. Analysis of patient muscle transcriptomes revealed strong enrichment of senescence and senescence-associated secretory phenotype (SASP) programs that correlated with DUX4 activity, clinical severity, and histopathological changes. Notably, these signatures were detectable even in STIR-negative muscles, defining a prodystrophic state characterized by early molecular alterations preceding overt MRI-detectable inflammation and highlighting their potential utility as early biomarkers of disease activity. Using an FSHD mouse model, we show that DUX4-induced muscle injury rapidly triggers senescence, which then progressively expands. Fibroadipogenic progenitors and macrophages emerged as the principal senescent populations and key sources of pro-inflammatory and profibrotic SASP signals. Importantly, senescence was therapeutically modifiable. Treatment with the nucleoside reverse transcriptase inhibitor lamivudine (3TC), which inhibits LINE-1 reverse transcriptase activity, significantly reduced senescence, inflammation, and fibrosis while promoting muscle regeneration. These findings identify cellular senescence as a tractable driver of FSHD and warrant senotherapeutic strategies, particularly lamivudine, for clinical intervention in FSHD.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pediatrics and Lillehei Heart Institute, University of Minnesota, Minneapolis, United States of America.
- John Walton Muscular Dystrophy Research Centre, NIHR Newcastle Biomedical R, Newcastle University and Newcastle Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom.
- Department of Physical Medicine and Rehabilitation, Mayo Clinic, Rochester, United States of America.
- Masonic Institute on the Biology of Aging and Metabolism and Department of , University of Minnesota, Minneapolis, United States of America.
Förderung
- NIH
Zitieren
APA
Jung, U., Wei, E., Mitanoska, A., Heher, P., Chen, K., Ahsan, H., Zhang, X., Tasca, G., Robbins, P. D., LeBrasseur, N. K., Kyba, M., & Bosnakovski, D. (2026). Cellular senescence mediates facioscapulohumeral muscular dystrophy. Journal of Clinical Investigation. https://doi.org/10.1172/jci207716
Vancouver
Jung U, Wei E, Mitanoska A, Heher P, Chen K, Ahsan H, et al. Cellular senescence mediates facioscapulohumeral muscular dystrophy. Journal of Clinical Investigation. 2026. doi:10.1172/jci207716
BibTeX
@article{Jung2026,
author = {Jung, Usuk and Wei, Erdong and Mitanoska, Ana and Heher, Philipp and Chen, Kenric and Ahsan, Haseeb and Zhang, Xu and Tasca, Giorgio and Robbins, Paul D and LeBrasseur, Nathan K and Kyba, Michael and Bosnakovski, Darko},
title = {Cellular senescence mediates facioscapulohumeral muscular dystrophy},
journal = {Journal of Clinical Investigation},
year = {2026},
doi = {10.1172/jci207716}
}
EUVIMED